Trials / No Longer Available
No Longer AvailableNCT03559673
Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures
Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0994 Study
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- UCB Biopharma S.P.R.L. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- —
Summary
The objective of this Compassionate Use Program (CUP) is to provide continued access to Lacosamide (LCM) for monotherapy use for patients who were receiving LCM in SP0993 and SP0994 at the time of study unblinding and close of SP0994, and who benefited from the treatment per investigator assessment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lacosamide | Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses. |
Timeline
- First posted
- 2018-06-18
- Last updated
- 2019-10-31
Source: ClinicalTrials.gov record NCT03559673. Inclusion in this directory is not an endorsement.